Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

“Everyone at Scorpion is delighted to be selected as a Fierce 15 company from a pool of many worthy candidates. We consider it an important recognition of our work delivering the next generation of precision medicines that are effective against a wide spectrum of targets and enable people with cancer to live fuller, longer lives,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. “In under three years, we have assembled a world-class team of scientific leaders and advisors, attracted a blue-chip investor syndicate and built a diversified and deep pipeline of optimized drug-discovery programs. We look forward to continuing this momentum as we advance two of our lead programs, STX-478 and STX-721, toward investigational new drug applications in 2023, while also progressing our broader portfolio of more than 15 additional programs through discovery against a wide variety of biologically validated targets.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 20^th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Fierce Biotech

Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

About Scorpion

Scorpion is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.

Rebecca Willumson
Fierce Biotech
202-824-5050
rwillumson@questex.com

Scorpion Media:
Ravi Moorthy
Scorpion Therapeutics
ravi@scorpiontx.com

Scorpion Investor:
Hannah Deresiewicz
Stern Investor Relations, Inc.
Hannah.deresiewicz@sternir.com